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Congenital lung lesions are highly complex with respect to pathogenesis and treatment. Large-scale analytical methods, like
metabolomics, are now available to identify biomarkers of pathological phenotypes and to facilitate clinical management. Nuclear
magnetic resonance (NMR) is a unique tool for translational research, as in vitro results can be potentially translated into in vivo
magnetic resonance protocols. Three surgical biopsies, from congenital lung malformations, were analyzed in comparison with
one control sample. Extracted hydrophilic metabolites were submitted to high resolution 1H NMR spectroscopy and the relative
concentration of 12 metabolites was estimated. In addition, two-dimensional NMRmeasurements were performed to complement
the results obtained from standard monodimensional experiments. This is one of the first reports of in vitrometabolic profiling of
congenital lungmalformation. Preliminary data on a small set of samples highlights some altered metabolic ratios, dealing with the
glucose conversion to lactate, to the relative concentration of phosphatidylcholine precursors, and to the presence of myoinositol.
Interestingly some relations between congenital lung lesions and cancer metabolic alterations are found.
1. Introduction
Lung development is a highly regulated and coordinated pro-
cess, typified by stage specific changes in structure and func-
tion, which includes branchingmorphogenesis, angiogenesis,
sacculation, alveologenesis, and cytodifferentiation [1]. Con-
genital pulmonary disease is characterized by a wide variety
of abnormalities arising at different stages of the process [2].
Metabolomics is an emerging approach that uses analyt-
ical techniques, such as nuclear magnetic resonance (NMR)
[3] spectroscopy, or mass spectrometry (MS) [4], to achieve a
comprehensive global monitoring of metabolites and their
fluctuations in response to various stimuli.
Although gene/protein expressions schemes provide use-
ful clues to organs development and function, many factors
like posttranslational modifications, alternative gene func-
tions, or compartmentalization also raise important bio-
chemical changes. Therefore, metabolic profiling is essential
to completely describe the physiopathological state of a bio-
logical system.
Considerable efforts in this sense were devoted to human
lung cancer [5, 6] and to human lung injury [7], but very lim-
ited information is available about metabolic perturbations
arising in situ from congenital lung malformations.
The purpose of this study was to determine the feasibility
of tissue extraction and analysis of the main hydrosoluble
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Table 1: Specimens features summary.
Specimen Patient Type of malformation Sex of patient Age at surgery Surgical procedure
N. 1 A Bronchogenic cyst M 4 months Lobectomy
N. 2 B Congenital lobar emphysema M 6 months Lobectomy
N. 3 B Bronchopulmonary sequestration M 6 months Lobectomy
N. 4 C Control lung M 7 days Lung biopsy
metabolites of lung lesions biopsies from human.Three types
of congenital malformation were evaluated in comparison to
a control lung tissue.
Particular attention was paid to the lactate/glucose (Lac/
Glc) ratio and to choline (Cho) compounds, which are in-
volved in the phosphatidylcholine (PtdCho) synthesis and
catabolism.
Many reasons lead us to focus on these particular
metabolic pathways; first of all a hyperactive glycolysis as well
as the following increment of the Lac/Glc ratio is associated
with lung inflammatory state [7] and represents, for instance,
a diagnostic tool related to lung cancers [5, 6].
The principal argument to investigate PtdCho metabo-
lism,which actually include choline and glucose, is the crucial
role of this phospholipid as the main component of alveolar
surfactant [8].
Many data prove that a disturbed surfactant metabolism
plays a role in several neonatal lung diseases, such as con-
genital diaphragmatic hernia (CDH) [9]. A further prompt to
focus on glucose and choline pathways comes from the results
of Raman mapping and FTIR imaging studies on congenital
pulmonary airways malformations (CPAM), in which an
accumulation of PtdCho and glycogen was noted [10].
In addition, it is generally accepted that the cycle of Ptd-
Cho, the major phospholipid component of eukaryotic cells,
is affected by malignant proliferations; free choline and its
derivatives phosphocholine (PCho) and glycerophospho-
choline GPCho represent relevant biomarkers for diagnostic
and therapeutic tools [11].
Finally, NMR spectroscopy is a unique tool for trans-
lational research. NMR-based metabolomics can provide a
comprehensive information on the degree of organ dysfunc-
tion and the metabolic biomarkers discovered in vitro can be
translated into in vivo magnetic resonance spectroscopy
protocols.
2. Materials and Methods
2.1. Instrumentation and Reagents. 1H NMR experiments
were acquired on a Bruker Avance spectrometer operating at
500MHz (Bruker BioSpin, Germany).
Tissue homogenization was performed by Ultra Turrax
T25 Homogenizer (IKA, Germany). Water was ultrapure
(mQH
2
O) and solvents were of HPLC grade (Sigma Aldrich,
United States).
2.2. Tissue Extraction. Three biopsies were obtained from
pathological lung tissue of two infants who underwent
surgery for congenitalmalformations.The control biopsy was
from a newborn deceased on the 7th day of life. The samples
were immediately frozen in liquid nitrogen after collection
and stored at −80∘C. In Table 1 the characteristics of the tissue
sections are reported.
The frozen biopsies were put in plastic test tube and kept
dipped into liquid nitrogen during the homogenization pro-
cess. While samples N. 2, N. 3, and N. 4 were completely pul-
verized in ca 5 minutes, sample N. 1 proved resistant to
homogenization and a nucleus of tissue remained intact.
The specimens weight after homogenization ranged roughly
between 30 and 110mg. Immediately after weighting, a bipha-
sic extraction of metabolites was performed, following a pre-
viously reported protocol [12].The obtained dry extracts were
stored at –80∘C until NMR analysis.
2.3. NMR Spectroscopy
2.3.1. Data Acquisition. An aliquot of each aqueous extract
(corresponding to 30–50mg of frozen pulverized tissue) was
redissolved in 0.65mL of deuterated phosphate buffer at
pH7.4, containingNa
2
HPO
4
/NaH
2
PO
4
50mM,TSP−Na+-d
4
(sodium 3-trimethyl-silyl [2,2 3,3-d
4
] propionate) 0.1mM as
a frequency reference, and NaN
3
0.5mM to prevent bacterial
growth. The working temperature was 298K.
Standard monodimensional 1H spectra included flip-
angle pulses of 30∘ and residual solvent suppression by pre-
saturation applied during the 5 s relaxation delay.
Two-dimensional TOCSY [13] spectra were also acquired
and the acquisition scheme mlevphpr [14] included solvent
suppression by presaturation [15], applied along the 2 s relax-
ation delay, and mixing time of 80ms.
Spectra acquisition and processing were performed with
the Bruker software TOPSPIN.
2.3.2. Data Treatment. After FID apodization with a line
broadening window function, all 1D spectra were phased,
Fourier-transformed, and chemical-shift referenced.The sig-
nals overlapping made the direct integration of peaks area
impossible; therefore, a spectrummodeling (peak fitting) was
performed with ACD/Labs 10. The experimental spectrum
was divided in regions containing not more than 100 peaks
prior to modeling with a combination of Gauss and Lorentz
functions.
For the relative quantification of the metabolites of inter-
est each fitted integral was normalized versus the total area of
the spectrum and corrected for the numbers of protons asso-
ciated to the assigned peak. The normalization permitted
overcoming the differences in biopsies dimensions and ho-
mogenization and allowed for a comparison of metabolites
levels among pathological and control tissues.
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The error associated with eachmodeled peak integral was
calculated by the following formula:
ErrorModeled Peak Integral = Modeled Peak Integral
×
√Total RSS
Total Integral
,
(1)
where Total RSS stands for residual sum of squared differ-
ences between the calculated spectrum and original experi-
mental data, while Total Integral stands for the absolute inte-
gral of the spectral region used for fitting and RSS determi-
nation.
Only a small region of 2D TOCSY spectra (in the range
3.0–4.6 ppm) was used to evaluate the relative concentration
of free Cho and its derivatives PCho andGPCho; the diagnos-
tic cross peaks of the three compounds are generated by the
twomethylene groups adjacent to the quaternary ammonium
(see Figure 1). The height of significant cross peaks was mea-
sured with the software Sparky (NMR Assignment and Inte-
gration software) and the noise was taken as confidence limit
of the measure. The noise was estimated as the median of 30
randomly sampled absolute value data heights.
3. Results
The 1H-1D NMR analysis of aqueous extracts from surgical
biopsies provided an overview of the main hydrosoluble
metabolites. The relative concentration of the assigned meta-
bolites was obtained by normalizing each integral value, cor-
rected for the proton number, versus the total area of the
spectrum and is shown in Table 2 and Figure 2.
The most important differences of malformation tissues
versus control lung regarded the ratio lactic acid/glucose or
Lac/Glc (here intended as Lac/𝛽-D-glucose) (Table 3). This
parameter, that reflects an enhanced glycolysis to produce lac-
tic acid, was particularly high in bronchopulmonary seques-
tration and to a lesser extent in congenital lobar emphysema,
compared to the control lung and bronchogenic cyst samples.
The other metabolite that discriminated pathological
from healthy tissue was myoinositol whose level was lower in
the control lung compared to the three malformation sam-
ples.
Among the assigned compounds, the phosphatidyl-
choline precursors were included (namely, Cho, PCho, and
GPCho). In the adopted pH conditions the diagnostic peaks
of choline compounds, arising from the methyl groups of the
quaternary ammonium,were in the range 3.20–3.25 ppm; this
resulted to be a very crowded region where also glucose and
other compounds resonances were detected (Figure 3). In
particular PCho and GPCho could not be measured in the
control lung due to the overlapping of glucose signals that was
particularly concentrated in this sample. For the same reason
GPCho could not be determined in the bronchogenic cyst
tissue.
Apart from the mentioned inconvenience, the 1D NMR
analysis showed some remarkable variations. The level of the
free Cho decreased with the following order: congenital lobar
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Figure 1: Chemical structure of choline, phosphocholine, sn-
glycero-3-phosphocholine, and 𝛽,𝛾-dipalmitoyl-L-𝛼-phosphatidyl-
choline (principal component of pulmonary surfactant).
emphysema, bronchogenic cyst, bronchopulmonary seques-
tration, control lung. The level of PCho decreased with the
following order: congenital lobar emphysema, bronchogenic
cyst, bronchopulmonary sequestration (control lung not det-
ermined). The relative concentration of GPCho was noted to
be higher in congenital lobar emphysema than in broncho-
pulmonary sequestration.
The limits of 1D NMR analysis prompted us to exploit 2D
NMR TOCSY experiments to estimate the Cho compounds
level. Although the correlation of metabolite concentration
with TOCSY peaks intensity is not linear, it has been proved
that the variation of choline compounds signals reflects their
concentration difference [16] (Figure 4).
To overcome the inhomogeneity among biopsies dimen-
sions, and consequently of global spectra intensity, we foc-
used on the relative peaks intensity instead of comparing their
absolute values. In Table 3, we reported the ratio of PCho
and GPCho cross peak height; this ratio decreased with the
following order: congenital lobar emphysema, bronchopul-
monary sequestration, bronchogenic cyst, control lung.
Unfortunately, the cross peak of free Cho could not be taken
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Figure 2: Bar diagram representation of data reported in Table 2. Phosphocholine is not detected in control lung spectrum (concentration
below detection limit). Glycerophosphocholine cannot be observed in bronchogenic cyst and in control lung spectra, due to the overlapping
of glucose whose level is particularly high in the two samples.
Table 3: Metabolites ratio in lung neonatal tissues. The first three ratios are obtained by 1H 1D NMR results reported in Table 2. The
PCho/GPCho ratio is derived from 1H-1H 2D NMR analysis: diagnostic cross peak heights of PCho and GPCho are compared to give a
semiquantitative estimate of their relative concentration. Ratios and associated confidence limits are derived as reported in Experimental
Section.
Metabolites ratio Broncho pulmonary sequestration Bronchogenic cyst Congenital lobar emphysema Control lung
1D NMR 1D NMR 1D NMR 1D NMR
Lac/Glc 62.5 ± 0.5 3.91 ± 0.02 10.48 ± 0.07 3.87 ± 0.04
Lac/Creat 18.1 ± 0.2 11.9 ± 0.07 19.0 ± 0.1 24.2 ± 0.2
Myo/Glc 23.5 ± 0.1 1.44 ± 0.01 4.21 ± 0.02 0.457 ± 0.003
2D NMR 2D NMR 2D NMR 2D NMR
PCho/GPCho 5.6 ± 0.5 0.96 ± 0.04 7.0 ± 0.2 0.41 ± 0.02
into consideration because of overlapping with one of the
myoinositol cross peaks (Figure 4).
We observed that GPCho is clearly more concentrated in
the control lung than inmalformations, while on the contrary
PCho level is higher inmalformations than in control lung, as
it comes out from the qualitative observation of TOCSY
maps.
4. Discussion
The lung is a complex organ consisting of more than 40 dis-
tinct cell types derived from ectodermal, mesenchymal, and
endodermal compartments with a number of specialized
functions related to gas exchange, host defense, and ion trans-
port [17].
The spectrum of congenital lung lesions likely results
from disordered embryologic interactions, occurring during
the course of fetal lung development. Bronchopulmonary
sequestrations aremicroscopic cystic masses of nonfunction-
ing pulmonary, which have a blood supply originating from
the aorta rather than the pulmonary artery, and an absence of
communication with the bronchial tree. BPS is likely to arise
between the 4th and 8th week gestation during the pseudog-
landular period. Also most bronchogenic cysts develop dur-
ing this phase and it result from abnormal budding of the
foregut. congenital lobar emphysema usually develops during
the canalicular stage (16–26weeks gestation) and it is an over-
inflation and distension of one or more pulmonary lobes,
possibly secondary to a defect in the bronchial cartilage.
A detailed understanding of the biochemical processes
governing stage specific changes during lung maturation and
the eventual lesion onset is still lacking. Describing physio-
pathological lung development, at a molecular resolution,
could lead to new perspectives in treatment of congenital
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Figure 3: Selected region of 500MHz 1H 1DNMR spectra of tissues extracts. Different colors are used to distinguish different samples traces.
Attribution of signals arising from free choline, choline phosphorylated derivatives, myoinositol, and 𝛽-D-glucose are shown.
malformations either in prenatal or in postnatal period. Tis-
sue characterization of pulmonary malformation in infants
and children could be useful with the perspective to give valu-
able information about lung maturation, timing, lung repair,
and regeneration.
The aim of the this work was establishing a protocol for
the extraction of hydrophilicmetabolites from lung tissues, as
well as for their quantification by NMR, prior to embarking
on a large scale study to identify biomarkers of congenital
lesions.
The first challenge we met was related to the intrinsic
limitations of 1D NMR spectroscopy applied to a complex
mixture of unfractionated compounds as in the case of any
biological tissue extracts.The signals superposition was over-
come by peak fitting, and in addition 2D NMR spectroscopy
was exploited to get a semiquantitative estimate of Cho deri-
vatives concentrations.
Though being aware that biomarkers identification must
build on a statistically significant set of samples, we could
make some interesting observations that regarded, first of all,
the ratio Lac/Glc. An enhanced Glc utilization, a hallmark of
malignant transformation, was observed for pulmonary
sequestration and to a lesser extent for pulmonary emphy-
sema, while the level of bronchogenic cyst was very similar to
the control lung (Table 3).
It must be said that both Lac and Glc were higher in the
bronchogenic cyst and in the control samples than in the
remaining two samples. The investigation of a more numer-
ous sample will clarify this variability.
From the analysis of 1D NMR data it resulted as well that
myoinositol (Myo) accumulated in malformation tissues
compared to the control lung; interestingly the Myo level
decreased in the order pulmonary sequestration, pulmonary
emphysema, bronchogenic cyst, with the latter very similar
to the control lung. This evidence could be worthy of further
investigation, if it was considered thatmyoinositol is involved
in fetal lung maturation as reported by Fanos et al. [18].
The last remarkable finding, which seemed to discrimi-
nate the normal lung from malformations, was based on 2D
NMR analysis and regarded the ratio of PCho/GPCho cross
peak height; this ratio decreased with the following order:
pulmonary emphysema, pulmonary sequestration, broncho-
genic cyst, control lung. Again, the last two samples were
more homogeneous than the first two conditions. Interest-
ingly, there seems to be a link between the reported obser-
vations and what is already known in the field of cancer re-
search. It is generally accepted, in fact, that the cycle of Ptd-
Cho, the major phospholipid component of eukaryotic cells,
is affected by malignant proliferations [11]. This causes an
alteration of PCho and GPCho levels which can be detected
by high resolution NMR; in particular an elevated size of
PCho generally reflects a high rate of cell proliferation, while
the spectral parameter PCho/GPCho has the role of malig-
nancy indicator in cancer [19].
5. Conclusions
The comprehension of biological mechanisms and timing
related to congenital lung malformations is still incomplete.
Numerous studies and clinical trials have focused on the role
of surfactant in lung maturation and function; much atten-
tion has been devoted also to the effect of surfactant defi-
ciency in preterm infants and in neonatal lung diseases. In
spite of that, a more detailed picture of the biochemical path-
ways involved in lung lesions onset during pregnancy could
have positive outcomes both on diagnostic and therapeutic
strategies of pediatric management.
To the best of our knowledge this is one of the first appli-
cations of metabolomics to human tissues derived from con-
genital lung lesions.
Although limited to a small set of samples this study high-
lights some altered metabolic ratios, dealing with the glucose
conversion to lactate, to the relative concentration of PtdCho
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Figure 4: Selected region from 500MHz TOCSYNMR spectra of tissues aqueous extracts.The cross peaks arising from free choline, choline
phosphorylated derivatives, and myoinositol are marked and labeled.
hydrosoluble precursors and to the presence of myoinositol.
Interestingly, some unexpected relations between congenital
lung lesions and cancer metabolic alterations are found.
Further investigation of the regulation of these metabolic
traits can have a manifold outcome: first of all, the translation
of in vitroNMRfindings to in vivoMRS (Magnetic Resonance
Spectroscopy) diagnosis of fetal lung maturity and develop-
ment.
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